A red-hot anti-aging strategy quietly passed its first test earlier this year after 14 volunteers took drugs meant to kill off old, toxic cells in their bodies.
The small study in people with lung disease, reported in January, is being billed as the first attempt at “senolytics,” or employing drugs to clear people’s bodies of aged, toxic cells. Some researchers think this strategy could eventually be employed in healthy people to delay aging.
“This gives us to some extent a green light to go on to larger trials,” says James Kirkland, a Mayo Clinic professor who helped lead the trial, carried out in clinics in Texas and at Wake Forest University starting in 2016.
Patients took two pills that Kirkland and his colleagues believed could selectively get rid of aged cells: the leukemia drug dasatinib and a supplement called quercetin.
It is early days for drugs meant to slow aging, and some breathed a sigh of relief that patients in this first-of-a-kind study didn’t suffer serious side-effects from the drugs. “My worry is we should not leap into this too fast, because if there’s a mistake or something we don’t understand, it could set the field back,” says Judith Campisi, a professor at the Buck Institute for Research on Aging in Novato, California.
This was a pilot trial—not even in the first phase of a three-part sequence of trials needed to win approval by the US Food and Drug Administration. So, officially, it showed nothing about aging at all.
All 14 patients suffered from a fatal, hard-to-treat lung condition called idiopathic pulmonary fibrosis, which explains why they were willing to participate in the experiment. The doctors found that nine doses of the two pills over three weeks did seem to improve patients’ ability to walk a bit farther in the same amount of time, and several other measures of well-being.
A bubble of commercial enthusiasm has been building around the idea that aging could be postponed, or its effects tempered, using drug treatments. A company called Unity Biotechnology of Brisbane, California, is developing two senolytic drugs, the first of which is in a phase 1 clinical trial for osteoarthritis—it’s being injected into people’s knees. Campisi is a cofounder of Unity, and Kirkland also holds shares in the public company, which is currently worth about half a billion dollars.
Image Credit: James Kirkland, Mayo Clinic professor. Mayo Clinic
News This Week
Nature wades through the literature on the new coronavirus — and summarizes key papers as they appear: 1 June — Positive coronavirus test is no guarantee of infectiousness People with COVID-19 are unlikely to [...]
In April, blood clots emerged as one of the many mysterious symptoms attributed to Covid-19, a disease that had initially been thought to largely affect the lungs in the form of pneumonia. Quickly after came [...]
Scientists from the University of Maryland School of Medicine (UMSOM) developed an experimental diagnostic test for COVID-19 that can visually detect the presence of the virus in 10 minutes. It uses a simple assay [...]
Rheumatologists at the University of Alberta are flagging similarities between the deaths of some COVID-19 patients and those with rheumatic illnesses, and are testing proven rheumatic treatments to see whether they help against [...]
Next-gen nano technologies that can prevent infection and diagnose disease are set to transform the medical industry as this important UniSA research is awarded more than $2 million dollars under the National Health and [...]
In late December last year, Dr. Li Wenliang began warning officials about a novel coronavirus in Wuhan, China, but was silenced by the police before tragically succumbing to the disease two months later. Meanwhile, [...]
Almost 10 weeks into the pandemic, COVID-19 is continuing to surprise and baffle health experts. In fact, experts' picture of exactly how COVID-19 might play out in the body is now quite different to [...]
EPFL scientists have developed a new computational approach to create artificial proteins, which showed promising results in vivo as functional vaccines. This approach opens the possibility to engineer safer and more effective vaccines. Vaccines [...]
A group of tiny RNA that should attack the virus causing COVID-19 when it tries to infect the body are diminished with age and chronic health problems, a decrease that likely helps explain why [...]
Purple rashes, swollen legs, clogged catheters and sudden death — blood clots, large and small, are a frequent complication of COVID-19, and researchers are just beginning to untangle why. For weeks, reports have poured [...]
Coronavirus vaccine trials are underway around the world. China’s hoping it can be first for ‘redemption’
In a medical centre in the eastern city of Xuzhou, a few dozen healthy adults have become some of the first to trial a vaccine candidate for the coronavirus. They are among a small [...]
A team of researchers hailing from Harvard and Université de Montréal today launched Epitopes.world, an AI-powered, interactive platform designed to facilitate COVID-19 vaccine development. It’s built atop an algorithm — CAMAP — that generates predictions for potential [...]
The "Human Brain/Cloud Interface" paper had more views that 99% of Frontiers articles. It has now been added to Frontier's "Nanotechnologies in Neuroscience and Neuroengineering" ebook which is available for download. Contributors: Frank J. [...]
This is the full-length version of this post. You can read the condensed version, which appeared as an opinion article in the Washington Post, here. The coronavirus pandemic pits all of humanity against the virus. The [...]
European photonics scientists are developing an ultrasensitive laser sensor that detects coronavirus at the earliest point of infection from a saliva or nasal swab in minutes. Responding to the European Commission’s Express Calls to [...]
Understanding how COVID-19 attacks the human body is essential to developing an effective treatment or vaccine to stop the global pandemic — but there's still so much we don't know about how it can kill us. As [...]